Treatment with four different BRD4 inhibitors reduces the expression of super-enhancer-associated oncogenes, such as MYC, E2F1, BCL6 and PAX5, and reduces diffuse large B cell lymphoma cell proliferation. The gene discussed is BRD4; the disease is diffuse large B-cell lymphoma.